Table 1 Selected characteristics of prostate cancer patients with available genetic data from the REQUITE cohort that assessed the EORTC QLQ-C30 Fatigue Scale and at least one Multidimensional Fatigue Inventory dimension in a sub-cohort up to two years following external beam radiotherapy
From: Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients
EORTC QLQ-C30 Fatigue Scale | Multidimensional Fatigue Inventory | |
|---|---|---|
Characteristic | N = 1381a | N = 877a |
Country | ||
Belgium | 296 (21%) | 0 (0%) |
France | 211 (15%) | 209 (24%) |
Germany | 71 (5%) | 70 (8%) |
Italy | 150 (11%) | 149 (17%) |
Netherlands | 61 (4%) | 0 (0%) |
Spain | 241 (17%) | 242 (28%) |
UK | 345 (25%) | 201 (23%) |
USA | 6 (<1%) | 6 (1%) |
Age at enrolment (years) | ||
Median (Range) | 70 (46–88) | 70 (46–88) |
BMI (kg/m²) | ||
<25 | 356 (26%) | 213 (24%) |
25–30 | 719 (52%) | 467 (53%) |
>30 | 301 (22%) | 196 (22%) |
History of depressionb | ||
Yes | 106 (8%) | 49 (6%) |
No | 1275 (92%) | 828 (94%) |
Smoking Status | ||
Never | 522 (38%) | 351 (40%) |
Former | 690 (50%) | 418 (48%) |
Current | 163 (12%) | 108 (12%) |
Tumour Sizec | ||
T1/T2/MRI not visible | 356 / 656 / 4 (74%) | 278 / 424 / 4 (81%) |
T3/T4 | 325 / 24 (25%) | 158 / 6 (19%) |
Nodal Involvement | ||
NX | 219 (16%) | 185 (21%) |
N0 | 1095 (79%) | 653 (74%) |
N1 | 65 (5%) | 39 (4%) |
Prostate-Specific Antigen (ng/mL), pre-diagnostic biopsy | ||
≤10 | 757 (59%) | 512 (62%) |
11-20 | 293 (23%) | 183 (22%) |
≥21 | 227 (18%) | 137 (16%) |
ISUP Grade | ||
1 (Gleason score: 2–6) | 234 (17%) | 168 (19%) |
2 (Gleason score: 3 + 4) | 454 (33%) | 286 (33%) |
3 (Gleason score: 4 + 3) | 339 (25%) | 235 (27%) |
4 (Gleason score: 8) | 171 (12%) | 93 (11%) |
5 (Gleason score: 9–10) | 178 (13%) | 93 (11%) |
D’Amico Risk Classificationd | ||
Low Risk | 102 (8%) | 82 (10%) |
Intermediate Risk | 601 (44%) | 420 (49%) |
High Risk | 651 (48%) | 357 (42%) |
Prior Prostatectomy | ||
Yes | 420 (30%) | 236 (27%) |
No | 961 (70%) | 641 (73%) |
Hormone Therapy | ||
None | 395 (29%) | 281 (32%) |
Short-term ( ≤ 6 months) | 782 (57%) | 477 (54%) |
Long-term ( > 6 months) | 204 (15%) | 119 (14%) |
Radiotherapy | ||
EBRT | 1381 (100%) | 877 (100%) |
Dose per fraction (Gy) | ||
≤2 | 1034 (75%) | 871 (99%) |
>2 | 347 (25%) | 6 (1%) |
Total dose (Gy) | ||
≤72 | 590 (43%) | 214 (24%) |
74–76 | 557 (40%) | 477 (54%) |
>76 | 232 (17%) | 185 (21%) |
Pelvic Radiotherapy | ||
Yes | 434 (31%) | 333 (38%) |
No | 947 (69%) | 544 (62%) |
